PANG — Pangaea Oncology SA Balance Sheet
0.000.00%
- €55.40m
- €58.08m
- €8.00m
- 44
- 11
- 67
- 31
Annual balance sheet for Pangaea Oncology SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | Interim Report | ARS | ARS | Interim Report |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1.17 | 1.04 | 2.93 | 8.51 | 2.79 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3.67 | 3.97 | 4.08 | 4.38 | 6.42 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 5.13 | 5.49 | 7.52 | 13.3 | 9.75 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.639 | 0.553 | 0.429 | 0.353 | 0.545 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 16.9 | 17 | 20.8 | 28.4 | 28.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.01 | 4.68 | 3.18 | 2.72 | 6.86 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 8.56 | 8.72 | 6.76 | 5.49 | 10.5 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 8.31 | 8.24 | 14.1 | 22.9 | 18 |
Total Liabilities & Shareholders' Equity | 16.9 | 17 | 20.8 | 28.4 | 28.4 |
Total Common Shares Outstanding |